---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-274318"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:47:20.873770+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics reports Q3 2025 net loss of $26.0M; cash $174M into late 2026

## Summary
- Net loss $26.0M ($0.35/sh) vs $15.1M ($0.21) in Q3 2024; R&D spend $20.3M up 69% YoY.
- Cash $174M as of Sep 30, 2025, down from $227M at Dec 31, 2024; runway into late 2026.
- Clinical: VMT-α-NET cohort 3 opened June 2025, 8 patients enrolled; favorable safety in 55 patients.
- VMT01 melanoma: 5 patients dosed at 3.0 mCi (monotherapy or +nivolumab) as of Oct 31, 2025.
- PSV359 FAP-α therapy: 3 patients treated as of Oct 31, 2025.

## SEC filing metadata
- accession: 0001193125-25-274318
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312525274318/0001193125-25-274318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312525274318/catx-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-274318
- JSON: https://secwatch.observer/filing/0001193125-25-274318.json
- Plain text: https://secwatch.observer/filing/0001193125-25-274318.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.